COMMUNIQUÉS West-GlobeNewswire

Cannabix Technologies Inc. Closes $4.6 Million Bought Deal Private Placement and $977,500 Concurrent Non-Brokered Private Placement

07/12/2017 - 15:07

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE:BLO) (the “Company”) is pleased to [...]

CohBar Announces the Appointment of Dr. John Amatruda to its Board

07/12/2017 - 15:00

MENLO PARK, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- CohBar, Inc. (OTCQX:CWBR) (TSXV:COB.U), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related [...]

INSYS Therapeutics Starts Proof-of-Concept Study of Epinephrine Nasal Spray for Anaphylaxis

07/12/2017 - 15:00

PHOENIX, Dec. 07, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY ) (“INSYS” or “the company”), announced today that it has started a proof-of-concept study of two formulations of epinephrine nasal spray [...]

The Ensign Group, Inc. Increases Quarterly Dividend to $0.045 Per Share

07/12/2017 - 15:00

MISSION VIEJO, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (NASDAQ: ENSG ), the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, home health care, hospice care [...]

Rafael Pharmaceuticals to Present New Data Validating Efficacy of CPI-613 in Treating Acute Myeloid Leukemia at the 2017 American Society of Hematology Annual Meeting & Exposition

07/12/2017 - 14:55

Newark, NJ, Dec. 07, 2017 (GLOBE NEWSWIRE) -- CPI-613 is Rafael Pharmaceuticals' lead drug candidate, a first-in-class anticancer compound designed to disrupt the altered energy production pathways in cancer cells by [...]

XOMA Announces Exclusive License Agreement for XOMA 358 with Rezolute, Inc.

07/12/2017 - 14:35

Expands portfolio of partner-funded programs $240 million in potential milestone payments Royalties ranging from the high single-digits to mid-teens on net sales Beyond XOMA 358, XOMA adds three additional programs to [...]

AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc.

07/12/2017 - 14:30

LOUISVILLE, Colo., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Rezolute , Inc. (“Rezolute” or the “Company”) (OTCQB:ANTB), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies [...]

Yield10 Bioscience CSO Dr. Kristi Snell to Present at CanolaWeek 2017

07/12/2017 - 14:30

WOBURN, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ: YTEN ) announced that CSO Kristi Snell, Ph.D., will be presenting today on a panel being held at the CanolaWeek 2017 conference. Dr. [...]

Kalytera Announces Initiation of Phase 2 Clinical Study in Prevention of Graft Versus Host Disease and Agreement with The Salzman Group of Israel to Manage and Partially Fund the Study to be Led by a World Class Team

07/12/2017 - 14:30

SAN FRANCISCO and TEL AVIV, Israel, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX-V: KALY ) and (OTCQB:KALTF) (the " Company " or " Kalytera ") today announced the initiation of a Phase 2 clinical [...]

Gala Global Inc. Announces Name Change and Shift in Business Strategy

07/12/2017 - 14:15

IRVINE, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Gala Global, Inc. (OTCBB: GLAG ) announces its filing a name change to Gala Pharmaceuticals Inc. The name change more closely aligns Gala Pharmaceuticals Inc., (GPI) to [...]

Entellus Medical Announces Definitive Agreement to be Acquired by Stryker Corporation for a Purchase Price of $24.00 Per Share in Cash

07/12/2017 - 14:15

PLYMOUTH, Minn., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ: ENTL ) announced today a definitive merger agreement by which Stryker Corporation (NYSE: SYK ) will acquire Entellus in an all cash [...]

Vericel Enters into Expanded $25 Million Debt Facilities with Silicon Valley Bank and MidCap Financial to Support Accelerating MACI Uptake and Increased Epicel Usage

07/12/2017 - 14:00

CAMBRIDGE, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL ), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, [...]

Tauriga Sciences, Inc. Confirms Multiple Initial Customer Orders for its Licensed Cupuacu Butter Lip Balm Product

07/12/2017 - 14:00

NEW YORK, NY, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or the “Company”), engaged in building business through the development, distribution, and licensing of proprietary [...]

iCAD Announces Study Demonstrating Economic and Health Benefits of Intraoperative Radiation Therapy (IORT) for Early-Stage Breast Cancer Treatment

07/12/2017 - 14:00

Lifetime cost-effectiveness analysis reveals $630 million annual cost savings, less radiation exposure and better quality of life for patients compared to external beam radiation therapy NASHUA, N.H., Dec. 07, 2017 ( [...]

aTyr Pharma to Participate at the BMO Prescriptions for Success Healthcare Conference

07/12/2017 - 14:00

SAN DIEGO, Dec. 07, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat patients suffering [...]

Iovance Biotherapeutics to Webcast Analyst Day on Wednesday, December 13, 2017

07/12/2017 - 14:00

SAN CARLOS, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) [...]

BeyondSpring to Webcast Key Opinion Leader Event in NYC on Dec. 14, 2017

07/12/2017 - 14:00

NEW YORK, Dec. 07, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI ) (“BeyondSpring” or the “Company”), a late-stage clinical biopharmaceutical company focusing on the development of a pipeline of innovative [...]

Jounce Therapeutics to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference

07/12/2017 - 14:00

CAMBRIDGE, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE ), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers [...]

India Globalization Capital Launches New Corporate Websites Highlighting Canna-Pharmaceutical Compound Portfolio

07/12/2017 - 14:00

BETHESDA, Md., Dec. 07, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American:IGC), today announced that it has launched two new websites to detail the Company’s cannabinoid pipeline for the [...]